26 July 2018
Visiongain has launched a new pharma report Global Alzheimer’s Disease Therapeutics and Diagnostics Market : Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies
Alzheimer’s Disease is reported to be the most common form of dementia in developed countries, with a prevalence of about 1% at the age of 65 and over 25% in people older than 85 years of age. Currently, advances in diagnostic technologies remain moderate and the Alzheimer’s Disease biomarker market is still in its infancy. It is expected that several diagnostic tools in the future will offer an accurate assessment of whether an individual has Alzheimer’s Disease, rather than one definitive diagnostic tool.
The lead analyst of the report commented the Alzheimer’s disease therapeutics market has been stagnant over the last few years, with many drugs failing late stage clinical trials. The overall AD market has experienced a slow growth in revenues due to the patent expiries of key drugs in major markets. There is a more positive outlook in the diagnostics market with advances in blood-based biomarkers, they are making a huge impact on clinical research of Alzheimer’s drug candidates. The Alzheimer’s Disease market will experience steady growth driven by the rising prevalence of AD and the entry of disease-modifying therapies (DMTs), including the passive immunotherapies, solanezumab, gantenerumab, and BACE inhibitors, verubecestat, which will have significant uptake in major markets”
Leading companies featured in the report include Pfizer, Eisai, Actavis, Lundbeck, Daiichi Sankyo, Novartis, TauRx, vTv Therapeutics, Eli Lilly, Amarantus Biosciences Holdings, Piramal Enterprises, GE Healthcare, Navidea, DiaGenic.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports discussing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
11 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.